Evidence map›Paper›PMID 42466005›Full record

Trial reportFrontiers in pharmacology2026

Pharmacokinetics and safety of SHR0302, a selective JAK1 inhibitor, in Chinese patients with hepatic impairment.

Jiajia Mai, Hongda Lin, Min Wu, Di Wang, Hong Zhang, Qinglong Jin, Chong Chen

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04293029 (Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04293029 phase1completednot on this map

Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study

TypeinterventionalSponsorJiangsu HengRui Medicine Co., Ltd.Ran2020 to 2020Enrolled24ConditionsHepatic ImpairmentArmsSHR0302
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiajia MaiDepartment of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, Jilin, China.
Hongda LinClinical Pharmacology Department, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu, China.
Min WuDepartment of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, Jilin, China.
Di WangDepartment of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, Jilin, China.
Hong ZhangDepartment of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, Jilin, China.
Qinglong JinDepartment of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun, China.
Chong ChenAbdominal Ultrasound Department, The First Hospital of Jilin University, Changchun, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To evaluate the effects of mild and moderate hepatic impairment on the pharmacokinetics and safety of SHR0302. Methods: This open-label, parallel-group study enrolled 24 Chinese subjects, including subjects with normal hepatic function and those with mild or moderate hepatic impairment (8 per group). All subjects received a single oral dose of SHR0302 (8 mg). Plasma PK parameters of SHR0302 and its metabolite, SHR161279, were assessed and compared across groups. Safety was evaluated throughout the study. Results: Mild hepatic impairment had minimal effect on the exposure of SHR0302. In subjects with moderate hepatic impairment, the C Conclusion: Mild and moderate hepatic impairment had minimal effect on SHR0302 exposure. Based on the single-dose pharmacokinetic and safety data, dose adjustment of SHR0302 may not be necessary in patients with mild or moderate hepatic impairment. Clinical Trial Registration: https://clinicaltrials.gov/, identifier NCT04293029.

Indexed as

clinical trialhepatic impairmentJAK1 inhibitorpharmacokineticsSHR0302

Identifiers

PMID42466005
PMCPMC13373095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.